Injectafer denied due to quantity / dose limits by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Imposes Quantity Limits on Injectafer — and How to Appeal When They Block Your Care

Injectafer (ferric carboxymaltose) is an intravenous iron product typically administered in one or two infusion sessions to replete iron stores. BlueCross BlueShield quantity-limit denials for Injectafer typically arise when the plan's system determines that the number of doses or total infusions requested exceeds a pre-set ceiling within a defined time period. These administrative limits are designed around a "typical" course of therapy and do not account for patients with ongoing losses, malabsorption, or conditions requiring repeated repletion cycles.

## Why This Denial Is Appealable

The FDA-approved prescribing information for Injectafer specifies the approved dosing parameters for the labeled indications. BCBS's quantity limit is an administrative construct; when a patient's clinical situation — such as ongoing iron loss from a chronic condition, inadequate repletion after an initial course, or a comorbidity driving continued iron deficit — requires additional infusions consistent with the approved label, the quantity limit does not constitute a valid clinical basis for denial. Your physician's documentation of the ongoing clinical need is the foundation of the appeal.

## Federal Appeal Framework

• Internal appeal: File under ACA §2719 or ERISA §503. Request the specific quantity-limit policy and the clinical rationale for its application to your case.
• External review: If the internal appeal is denied, escalate to an IRO within the approximately four-month window specified in the denial letter.
• Expedited review: Available if the patient's anemia is symptomatic or clinically urgent; request it at every level.

## Concrete Appeal Steps and Timeline

1. Obtain the BCBS quantity-limit coverage policy for Injectafer and identify the specific threshold that was exceeded. 2. Have your physician document the clinical basis for the additional infusion(s) — including ongoing losses, laboratory evidence of inadequate repletion, and the underlying condition driving continued need. 3. Confirm that the total requested amount remains within parameters described in the FDA-approved prescribing label for your indication. 4. Submit the internal appeal with the prescriber letter by the deadline on the denial notice; escalate to IRO if denied.

## Documentation to Gather

• Diagnosis confirmation: Current and serial lab results showing iron indices and hemoglobin, documenting either ongoing deficit or recurrence after initial repletion.
• Underlying condition documentation: Clinical notes confirming the diagnosis responsible for ongoing iron loss or impaired absorption (e.g., inflammatory bowel disease, chronic kidney disease, uterine pathology, bariatric surgery history).
• Clinical severity: Physician notes on symptom burden, functional status, and the clinical risk of under-treatment.
• Prescriber medical-necessity letter: Statement that the requested additional infusion(s) are medically necessary given the patient's clinical course, consistent with the FDA-approved label, and supported by the applicable clinical guideline organization.

## Criteria-Mapping Structure

Obtain BCBS's quantity-limit policy for Injectafer. For each quantity restriction cited as the basis for denial, provide a corresponding chart entry: the lab result demonstrating ongoing need, the physician note documenting the clinical rationale, and a reference to the FDA label parameter that accommodates the requested quantity. Addressing the policy restriction directly with dated clinical evidence is the most effective path to reversal.